Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin for the treatment of sickle cell disease, and company updates commonly address PIONEER trial data, markers of hemolysis and anemia, and sickle cell disease collaborations.
FULC news also covers quarterly financial results, corporate presentations, Nasdaq inducement equity grants, board composition, and updates to the company's pipeline and financial position as it advances small molecules that modulate gene expression.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) has announced the pricing of a public offering of 6,600,000 shares of its common stock at $19.00 per share, aiming for total gross proceeds of approximately $125 million before expenses. The offering is expected to close on August 16, 2021. Additionally, underwriters have a 30-day option to purchase up to 990,000 extra shares. The offering is being conducted under a shelf registration statement and involves joint bookrunning managers SVB Leerink, Piper Sandler & Co., and Stifel.
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has announced a public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. The offering is managed by SVB Leerink, Piper Sandler & Co., and Stifel. Fulcrum plans to use the proceeds to advance its clinical development programs, including drugs for rare diseases. The offering is subject to market conditions and follows a previously filed shelf registration with the SEC.
Fulcrum Therapeutics reported positive interim results from a Phase 1 trial with FTX-6058 for sickle cell disease, demonstrating proof of mechanism and biology. The company plans a Phase 1b trial in sickle cell patients in Q4 2021. Financially, Fulcrum's cash and equivalents rose to $125.6 million by June 30, 2021, supporting operations into Q1 2023. Collaboration revenue increased to $4.4 million, while net loss for Q2 2021 was $19.6 million. The firm remains focused on advancing therapies for rare genetic diseases.
Fulcrum Therapeutics (Nasdaq: FULC) announced positive interim results from its Phase 1 trial of FTX-6058, showing a mean 4.5-fold induction of HBG mRNA and a 4.2-fold increase in F-reticulocytes at the 10mg dose after 14 days. The investigational drug, targeting hemoglobinopathies, was well tolerated with no serious adverse events reported. The company plans to initiate a Phase 1b trial in sickle cell patients by Q4 2021 and submit an IND application for non-sickle cell hemoglobinopathies by year-end 2021, highlighting a potential advancement in treatment options.
Fulcrum Therapeutics (Nasdaq: FULC) announced it will release its second quarter 2021 financial results on August 10, 2021, prior to market open. A conference call and webcast are scheduled for 8:00 a.m. ET to discuss the results and recent corporate developments. The company specializes in developing treatments for genetically defined rare diseases. It has advanced losmapimod into Phase 2 clinical trials for facioscapulohumeral dystrophy and FTX-6058 into Phase 1 clinical trials for sickle cell disease and beta-thalassemia.
Fulcrum Therapeutics (NASDAQ: FULC) announced results from its Phase 2b ReDUX4 trial of losmapimod for facioscapulohumeral muscular dystrophy (FSHD). While the primary endpoint of DUX4-driven gene expression was not met, significant clinical benefits were observed, including reduced muscle fat infiltration and improved functional outcomes. Losmapimod was well tolerated, with no serious adverse events related to treatment. The company plans to engage with the FDA regarding future regulatory steps in H2 2021. Overall, these results support losmapimod as a potential transformative therapy for FSHD.
Fulcrum Therapeutics (Nasdaq: FULC) will hold a conference call on June 24, 2021, at 8:00 am ET to discuss the results of the Phase 2b ReDUX4 trial involving losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD). The company is presenting multiple findings at the 28th Annual FSHD Society International Research Congress. These include efficacy and safety data from the trial. FSHD affects 16,000 to 38,000 patients in the U.S., with no approved treatments available. Losmapimod has received FDA Fast Track designation.
Fulcrum Therapeutics (Nasdaq: FULC) has received Fast Track designation from the FDA for losmapimod, aimed at treating facioscapulohumeral muscular dystrophy (FSHD), a disease with no approved therapies. This designation assists in expedited drug development and review. Recent Phase 2b trial data from ReDUX4 will be reported at the FSHD International Research Congress on June 24-25, 2021. Losmapimod, previously granted Orphan Drug Designation, has been evaluated in over 3,600 subjects without safety signals reported.
Fulcrum Therapeutics (Nasdaq: FULC) announced its participation in the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 11:00 a.m. ET. The presentation will provide a corporate overview of the company, which focuses on genetically defined rare diseases. Investors can access a live audio webcast on Fulcrum's Investor Relations website, with an archived replay available for 90 days. The company is advancing treatments for conditions like facioscapulohumeral muscular dystrophy and sickle cell disease.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) reported first quarter 2021 financial results, highlighting a cash position of $143.9 million, sufficient to fund operations into Q4 2022. Collaboration revenue surged to $4.8 million, up from $0.8 million YoY, attributed to partnerships with MyoKardia and Acceleron. Key clinical progress includes upcoming data from the Phase 2b ReDUX4 trial for facioscapulohumeral muscular dystrophy and the Phase 1 trial for sickle cell disease. The company has also appointed new leadership, enhancing its strategic capabilities.